España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Roche Holding
RHHVF
OTC
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$331.87
-3.69
-1.10%
At close: -
$278.84
-53.03
-15.98%
After Hours: Dec 19, 8:12 AM EDT
Get Report
Comment
Roche Holding (RHHVF) Forecast
News
Earnings
Roche Holding (RHHVF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Roche Holding (OTC:RHHVF) Stock
Roche Holding Stock (OTC: RHHVF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, January 30, 2025
Roche For 2025 Expects Mid-Single-Digit Sales...
Benzinga Newsdesk
Roche's Q4 Adj. EPS CHF18.80 Up From CHF18.57...
Benzinga Newsdesk
Tuesday, January 28, 2025
Roche's Genentech Reports Significant Surviva...
Benzinga Newsdesk
Monday, January 13, 2025
Roche's VENTANA ISH Test Secures FDA Clearanc...
Benzinga Newsdesk
Thursday, January 09, 2025
Roche's Digital Pathology Dx System Expands W...
Benzinga Newsdesk
Thursday, January 02, 2025
Reported Wednesday, Roche And Innovent Forge ...
Benzinga Newsdesk
Thursday, December 19, 2024
Genentech's Prasinezumab Phase IIb Study Miss...
Benzinga Newsdesk
Tuesday, December 10, 2024
Reported Earlier, Roche's Genentech Presents ...
Benzinga Newsdesk
Monday, December 09, 2024
Reported Sunday, Roche's Genentech Showcases ...
Benzinga Newsdesk
Thursday, December 05, 2024
FDA Accepts Genentech's sBLA For Columvi Comb...
Benzinga Newsdesk
Tuesday, November 26, 2024
Roche's Genentech Provides Update On SKYSCRAP...
Benzinga Newsdesk
Monday, November 25, 2024
Roche Wins FDA Approval For The First Diagnos...
Benzinga Newsdesk
Monday, October 14, 2024
Genentech's Evrysdi Two-Year Data Shows Promi...
Benzinga Newsdesk
Thursday, September 19, 2024
Roche's Genentech Phase III CENTERSTONE Study...
Benzinga Newsdesk
Friday, September 13, 2024
Reported Earlier, Roche's Genentech And Haloz...
Benzinga Newsdesk
Monday, September 09, 2024
Roche Expands AI-Driven Cancer Diagnostics Wi...
Benzinga Newsdesk
Thursday, July 25, 2024
Roche Holding H1 Adj. EPS CHF 10.23 Up From C...
Benzinga Newsdesk
Wednesday, July 17, 2024
Roche's Genentech Reveals Phase I Results Of ...
Benzinga Newsdesk
Friday, July 05, 2024
Reported Thursday, Roche's Genentech Halts SK...
Benzinga Newsdesk
Roche's Genentech Receives FDA Approval For V...
Benzinga Newsdesk
Tuesday, June 18, 2024
Roche's VENTANA DP 200 Digital System Approve...
Benzinga Newsdesk
Monday, June 17, 2024
Reported Saturday, Genentech's Phase III STAR...
Benzinga Newsdesk
Wednesday, May 29, 2024
Roche's Genentech Granted Priority Review By ...
Benzinga Newsdesk
Tuesday, May 28, 2024
Reported Earlier, Roche And Hitachi High-Tech...
Benzinga Newsdesk
Tuesday, May 21, 2024
Roche Announces That The FDA Granted Breakthr...
Benzinga Newsdesk
Thursday, May 16, 2024
Roche's Genentech Reports Phase Ib Results Fo...
Benzinga Newsdesk
Wednesday, April 17, 2024
Roche Announces Genentech's Subcutaneous Ocre...
Benzinga Newsdesk
Monday, April 15, 2024
Roche's Genentech Announces That Columvi Met ...
Benzinga Newsdesk
Wednesday, April 10, 2024
Roche Obtains CE Mark For First Companion Dia...
Benzinga Newsdesk
Tuesday, March 12, 2024
Roche Unveils navify Analytics For Optimal La...
Benzinga Newsdesk
Monday, February 26, 2024
Reported Earlier, Roche's Genentech Announced...
Benzinga Newsdesk
Tuesday, February 13, 2024
Roche Collaborates With PathAI To Expand Digi...
Benzinga Newsdesk
Thursday, February 01, 2024
Roche's Genentech Announces New 72-Week Data ...
Benzinga Newsdesk
Friday, January 26, 2024
Roche's Genentech Vabysmo New Long-Term Data ...
Benzinga Newsdesk
Tuesday, January 16, 2024
Roche Receives European Commission Approval O...
Benzinga Newsdesk
Tuesday, January 02, 2024
Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M
Vandana Singh
Tuesday, December 19, 2023
Roche navify Digital Solutions Earns Excell...
Benzinga Newsdesk
Monday, December 11, 2023
Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial
Vandana Singh
Roche's Genentech Presented New Data From Its...
Benzinga Newsdesk
Tuesday, December 05, 2023
Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation
Vandana Singh
Roche's Genentech Announces Phase III Results...
Benzinga Newsdesk
Monday, December 04, 2023
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
Vandana Singh
Tuesday, October 31, 2023
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
Vandana Singh
Friday, October 27, 2023
Roche's Genentech Announced That The FDA Has ...
Benzinga Newsdesk
Monday, October 23, 2023
Roche Agrees To Acquire Telavant, Including R...
Benzinga Newsdesk
Thursday, October 19, 2023
Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products
Vandana Singh
Wednesday, October 18, 2023
Roche's Genentech Announces Results From The ...
Benzinga Newsdesk
Tuesday, October 17, 2023
What's Going On Cancer Player Monte Rosa Therapeutics Stock Today?
Vandana Singh
Thursday, October 12, 2023
Roche's Genentech Presented New Clinical And ...
Benzinga Newsdesk
Wednesday, October 11, 2023
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
Vandana Singh
Show More
